IT1247472B - Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. - Google Patents

Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Info

Publication number
IT1247472B
IT1247472B ITPD910102A ITPD910102A IT1247472B IT 1247472 B IT1247472 B IT 1247472B IT PD910102 A ITPD910102 A IT PD910102A IT PD910102 A ITPD910102 A IT PD910102A IT 1247472 B IT1247472 B IT 1247472B
Authority
IT
Italy
Prior art keywords
preparation
biologically active
active components
microspheres containing
containing biologically
Prior art date
Application number
ITPD910102A
Other languages
English (en)
Inventor
Lanfranco Callegaro
Aurelio Romeo
Luca Benedetti
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of ITPD910102A0 publication Critical patent/ITPD910102A0/it
Priority to ITPD910102A priority Critical patent/IT1247472B/it
Priority to EP92401433A priority patent/EP0517565B1/en
Priority to EP99202579A priority patent/EP0979648A3/en
Priority to ES92401433T priority patent/ES2153355T3/es
Priority to DE69231507T priority patent/DE69231507T2/de
Priority to AT92401433T priority patent/ATE196991T1/de
Priority to JP4139012A priority patent/JPH07179363A/ja
Priority to CA002070095A priority patent/CA2070095C/en
Publication of ITPD910102A1 publication Critical patent/ITPD910102A1/it
Priority to US08/169,558 priority patent/US6066340A/en
Application granted granted Critical
Publication of IT1247472B publication Critical patent/IT1247472B/it
Priority to US09/231,353 priority patent/US6039970A/en
Priority to GR20000402482T priority patent/GR3034789T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Oggetto dell'invenzione è una composizione di microsfere ed un processo per la loro preparazione, a partire da polimeri semisintetici biodegradabili e bioriassorbibili e da singole molecole o loro miscele aventi attività farmacologiche, che permetta di mantenere inalterate le caratteristiche chimiche del polimero semisintetico impiegato, l'attività farmacologica o biologica delle molecole, garantendo un rilascio controllato in funzione dell'idrofilicità del sostituente chimico presente sul polimero semisintetico.
ITPD910102A 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. IT1247472B (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ITPD910102A IT1247472B (it) 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP92401433A EP0517565B1 (en) 1991-05-31 1992-05-26 Process for the preparation of microspheres containing biologically active components
EP99202579A EP0979648A3 (en) 1991-05-31 1992-05-26 Microspheres of esters of hyaluronic acid for controlled release of an active
ES92401433T ES2153355T3 (es) 1991-05-31 1992-05-26 Procedimiento para la preparacion de microesferas que contienen compuestos biologicamente activos.
DE69231507T DE69231507T2 (de) 1991-05-31 1992-05-26 Verfahren zur Zubereitung von biologisch aktiven Komponenten enthaltenden Mikrospheren
AT92401433T ATE196991T1 (de) 1991-05-31 1992-05-26 Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren
JP4139012A JPH07179363A (ja) 1991-05-31 1992-05-29 生物学的に活性な成分を含有するミクロスフェアの製造方法
CA002070095A CA2070095C (en) 1991-05-31 1992-05-29 Microspheres containing biologically-active components, processes for the preparation and uses
US08/169,558 US6066340A (en) 1991-05-31 1993-12-20 Process for the preparation of microspheres containing biologically active components
US09/231,353 US6039970A (en) 1991-05-31 1999-01-13 Process for the preparation of microspheres containing biologically active components
GR20000402482T GR3034789T3 (en) 1991-05-31 2000-11-08 Process for the preparation of microspheres containing biologically active components.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITPD910102A IT1247472B (it) 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Publications (3)

Publication Number Publication Date
ITPD910102A0 ITPD910102A0 (it) 1991-05-31
ITPD910102A1 ITPD910102A1 (it) 1992-12-01
IT1247472B true IT1247472B (it) 1994-12-17

Family

ID=11389598

Family Applications (1)

Application Number Title Priority Date Filing Date
ITPD910102A IT1247472B (it) 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Country Status (9)

Country Link
US (2) US6066340A (it)
EP (2) EP0517565B1 (it)
JP (1) JPH07179363A (it)
AT (1) ATE196991T1 (it)
CA (1) CA2070095C (it)
DE (1) DE69231507T2 (it)
ES (1) ES2153355T3 (it)
GR (1) GR3034789T3 (it)
IT (1) IT1247472B (it)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
IT1263144B (it) * 1993-02-04 1996-08-01 Lanfranco Callegaro Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
JPH0827018A (ja) * 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
CA2216919C (en) * 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres comprising a biocompatible polysaccharide
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
IT1294797B1 (it) 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
US6623732B1 (en) 1998-05-20 2003-09-23 Highchem Company, Ltd. Pharmaceutical formulation for nasal administration
JP4610735B2 (ja) * 1998-06-01 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ワクチン抗原およびアジュバントの粘膜送達のためのヒアルロン酸ポリマーの使用
US6824793B1 (en) 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
AU4673099A (en) 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
AU5624500A (en) * 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid microspheres for sustained gene transfer
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
EP1249247B1 (en) * 2001-03-30 2007-02-28 Chisso Corporation Pharmaceutical preparation for the treatment of gynecological diseases
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7276254B2 (en) * 2002-05-07 2007-10-02 Xerox Corporation Emulsion/aggregation polymeric microspheres for biomedical applications and methods of making same
US20050287135A1 (en) * 2002-05-17 2005-12-29 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US20040197264A1 (en) * 2003-04-04 2004-10-07 Alexander Schwarz Microspheres comprising therapeutic and diagnostic radioactive isotopes
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
ES2232287B1 (es) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de derivados polioxietilenados.
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
RU2518295C2 (ru) 2005-06-21 2014-06-10 Ксома Текнолоджи Лтд. IL-1бета-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ФРАГМЕНТЫ
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
ITMI20080981A1 (it) * 2008-05-27 2009-11-28 Fidia Advanced Biopolymers Srl Processo per la preparazione di microsfere di polimeri semi-sintetici
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
GB201017889D0 (en) * 2010-10-22 2010-12-01 Univ Dublin A polymeric nanoparticle
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
JP6684490B2 (ja) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
JP6373961B2 (ja) 2013-03-13 2018-08-15 バイオスフィア メディカル，インコーポレイテッド ラジオアイソトープ結合微粒子の組成物及び結合方法
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
EP3082797A4 (en) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2016207730A1 (en) 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
CN105663052B (zh) * 2016-02-05 2019-03-15 舒泰神（北京）生物制药股份有限公司 神经生长因子缓释微球制剂及其制备方法
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
WO2019241430A2 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
KR102296304B1 (ko) 2020-11-30 2021-09-01 조광용 고팽윤성 히알루론산 비드 겔 제조 방법
KR102366394B1 (ko) 2021-01-05 2022-02-23 조광용 고팽윤성 히알루론산 비드 겔
EP4313132A1 (en) 2021-03-31 2024-02-07 Vib Vzw Vaccine compositions for trypanosomatids
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (sv) 1985-03-01 1986-09-02 Pharmacia Ab Format alster och forfarande for dess framstellning
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
WO1988001213A1 (en) * 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5879359A (en) * 1992-08-03 1999-03-09 Fidia S.P.A. Biodegradable guide channels comprised of esters of hyaluronic acid for use in tissue repair as surgical aids
IT1268955B1 (it) * 1994-03-11 1997-03-18 Fidia Advanced Biopolymers Srl Esteri attivi di polisaccaridi carbossilici
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5939323A (en) * 1996-05-28 1999-08-17 Brown University Hyaluronan based biodegradable scaffolds for tissue repair

Also Published As

Publication number Publication date
ITPD910102A1 (it) 1992-12-01
EP0517565B1 (en) 2000-10-18
GR3034789T3 (en) 2001-02-28
US6039970A (en) 2000-03-21
DE69231507D1 (de) 2000-11-23
JPH07179363A (ja) 1995-07-18
EP0517565A2 (en) 1992-12-09
ES2153355T3 (es) 2001-03-01
US6066340A (en) 2000-05-23
DE69231507T2 (de) 2001-05-03
ATE196991T1 (de) 2000-11-15
EP0517565A3 (en) 1992-12-30
EP0979648A3 (en) 2000-10-04
EP0979648A2 (en) 2000-02-16
CA2070095C (en) 2000-04-25
CA2070095A1 (en) 1992-12-01
ITPD910102A0 (it) 1991-05-31

Similar Documents

Publication Publication Date Title
IT1247472B (it) Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
DK1030697T3 (da) Bionedbrydeligt polymerskelet
DE60029566D1 (de) In-vitro herstellung von transplantierbarem knorpelgewebe
MY119241A (en) Medical material and process for producing the same.
CA2107709A1 (en) Calcium Agent for Plants
FR2741628B1 (fr) Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
IL131063A (en) Bistable spring construction for a stent and other medical apparatus
ATE219108T1 (de) Polymere zur abgabe von stickstoffoxide in vivo
DE69434258D1 (de) Mikroverkapselte 1,2-benzazole
ES2062530T3 (es) Procedimiento para producir particulas pequeñas de moleculas biologicamente activas.
ES2181725T3 (es) Inhibidores de hiv proteasa.
ES2090836T3 (es) Procedimiento para la preparacion de microcapsulas polimeras que contienen substancias biologicamente activas.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
NZ508470A (en) Matrices formed of polymer and hydrophobic compounds for use in sustained release drug delivery
ES2069571T3 (es) Proceso de desnitrificacion biologica.
AU2243588A (en) Porous cellular ceramic biological support
DE69025831D1 (de) Elektronemittierende Vorrichtung; Herstellungsverfahren Elektronemittierende Vorrichtung, Herstellungsverfahren derselben und Anzeigegerät und Elektronstrahl- Schreibvorrichtung, welche diese Vorrichtung verwendet.
PT94882A (pt) Processo para a preparacao de arginina deiminase e de um agente anti-canceroso contendo esta enzima como ingrediente activo
DK1061948T3 (da) Præparat til vedvarende frigivelse af et fysiologisk aktivt polypeptid samt fremstilling deraf
DE69928524D1 (de) Biologisch aktive zusammensetzung
BR9903382A (pt) Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos
苏镜娱 et al. A Novel elemane-type sesquiterpenoid lactam Clavulinin
ES2066422T3 (es) Expresion de un arn multigenes con actividad de autoempalme.
FR2665362B1 (fr) Substance contenant, comme principe actif, une adenosine substitutee en n6 et son application.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19990614